Wiley appoints Karen N. Madden, Ph.D., to Board of Directors

JOHN WILEY & SONS, INC.

Dr. Madden joined the Board effective February 28, 2025; appointed to Audit Committee.
She is SVP & CTO of MilliporeSigma (Merck KGaA), bringing science and innovation expertise.
Annual cash retainer of $85,000 and restricted stock award of $130,000 under 2022 Omnibus Plan.
Board determined she is independent under NYSE rules; no material interest in related-party transactions.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karen N. Madden

Director

WLY · JOHN WILEY & SONS, INC.

Effective: 2025-02-28
Filed: March 5, 2025, 6:59 PM ET

the Board of Directors (the “Board”) has elected Dr. Karen N. Madden, to join the Board effective February 28, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen N. Madden was elected as Director at JOHN WILEY & SONS, INC..

Action: elected
Role: Director

Exact text from the filing

the Board of Directors (the “Board”) has elected Dr. Karen N. Madden, to join the Board effective February 28, 2025.

View on SEC.gov

JOHN WILEY & SONS, INC. filing history →

Source: SEC EDGAR

accession 0000107140-25-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.